Zydus Lifesciences Limited is an India-based global life sciences company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The Company is engaged in the business of integrated pharmaceutical operations. Its product portfolio includes active pharmaceutical ingredients (API), human formulations, animal health and veterinary, health, and wellness products. Its products include India formulations, Generics and Zydus biologics. The Company's products include Lipaglyn and Bilypsa (Saroglitazar), Ujvira (Trastuzumab emtansine biosimilar), Exemptia (Adalimumab biosimilar), Vivitra (Trastuzumab biosimilar) and Bryxta (Bevacizumab biosimilar). Its Zydus biologics covers various therapeutic areas, such as oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology and infectious illnesses, among others. The Company has a global presence and markets its products in the United States, India, Europe and emerging markets.

Employees

26,921

Sector

Pharmaceuticals

Calendar

14/02/2025 - Q3 2025 Earnings Release

More about the company

Quotes

Date	Price	Change	Volume
11/24/11	986.45 ₹	+1.26%	591,808
10/24/10	974.20 ₹	-0.84%	664,912
09/24/09	982.45 ₹	-1.27%	1,191,543
06/24/06	995.10 ₹	+1.75%	749,783
05/24/05	978.00 ₹	+0.79%	697,437

Delayed Quote NSE India S.E., December 11, 2024 at 01:16 pm IST

More quotes

Income Statement and Estimates

income-statement-evolution-chart ZYDUS-LIFESCIENCES-LIMITE

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

974.20INR

Average target price

1,083.36INR

Spread / Average Target

+11.21%

Consensus

Profit revisions

estimates-change-chart ZYDUS-LIFESCIENCES-LIMITE

Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart ZYDUS-LIFESCIENCES-LIMITE

Company calendar

Market Closed - NSE India S.E. Other stock markets 05:19:38 11/12/2024 pm IST			5-day change	1st Jan Change
986.45 ^INR	+1.26%		+0.44%	+43.13%

29/11	Zydus Lifesciences Limited Receives Demand Order-In-Original from Assistant Commissioner, Division Dehradun, Sector-7, Uttarakhand	CI
14/11	Nomura Adjusts Zydus Lifesciences' Price Target to INR1,030 From INR1,020, Keeps at Neutral	MT

Capitalization	98TCr 1.16TCr 1.1TCr 1.02TCr 906.24Cr 1.64TCr 1.81TCr 13TCr 4.68TCr 40TCr 4.34TCr 4.24TCr 1,75700Cr	P/E ratio 2025 *	22.1x	P/E ratio 2026 *	21.3x
Enterprise value	96TCr 1.13TCr 1.07TCr 993.09Cr 883.29Cr 1.59TCr 1.77TCr 12TCr 4.56TCr 39TCr 4.23TCr 4.14TCr 1,71200Cr	EV / Sales 2025 *	4.2x	EV / Sales 2026 *	3.78x
Free-Float	-	Yield 2025 *	0.61%	Yield 2026 *	0.66%

Zydus Lifesciences Limited Receives Demand Order-In-Original from Assistant Commissioner, Division Dehradun, Sector-7, Uttarakhand	29/11	CI
Nomura Adjusts Zydus Lifesciences' Price Target to INR1,030 From INR1,020, Keeps at Neutral	14/11	MT
Jefferies Adjusts Zydus Lifesciences' Price Target to INR1,380 From INR1,450, Keeps at Buy	13/11	MT
Zydus Lifesciences Posts Gains in Fiscal Q2 Consolidated Net Profit	13/11	MT
Zydus Lifesciences Limited, Q2 2025 Earnings Call, Nov 12, 2024	12/11
India's Zydus Life posts Q2 profit rise on steady US demand	12/11	RE
Zydus Lifesciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024	12/11	CI
Zydus Lifesciences Limited Receives in Principle Acceptability from World Health Organization for Zyvac Tcv	23/10	CI
Zydus Lifesciences Limited Receives Final Approval from USFDA for Fludrocortisone Acetate Tablets USP, 0.1 Mg	17/10	CI
Zydus Lifesciences to Start Phase 2 Trials of Desidustat for Sickle Cell Disease	14/10	MT
Zydus Lifesciences Limited and ICMR Initiate A Phase 2 Proof-Of-Concept Trial of Desidustat in Patients with Sickle Cell Disease	14/10	CI
Zydus Lifesciences Limited Receives Final Approval from USFDA for Paliperidone Extended-Release Tablets	10/10	CI
Zydus Lifesciences Gets Tentative Nod from US FDA for Enzalutamide Tablets	02/10	MT

Nomura Adjusts Zydus Lifesciences' Price Target to INR1,030 From INR1,020, Keeps at Neutral	14/11	MT
Jefferies Adjusts Zydus Lifesciences' Price Target to INR1,380 From INR1,450, Keeps at Buy	13/11	MT
Jefferies Upgrades Zydus Lifesciences to Buy From Hold, Adjusts Price Target to INR1,450 From INR1,210	28/08	MT
Jefferies Adjusts Zydus Lifesciences' Price Target to INR1,210 From INR1,070, Keeps at Hold	12/08	MT
Nomura Downgrades Zydus Lifesciences to Neutral From Buy, Adjusts Price Target to INR1,020 From INR988	21/05	MT

Zydus Lifesciences Limited Share Price

Equities

ZYDUSLIFE

INE010B01027

Pharmaceuticals

Valuation: Zydus Lifesciences Limited

Chart: Zydus Lifesciences Limited

Latest news: Zydus Lifesciences Limited

Last Transcript: Zydus Lifesciences Limited

Analysts' recommendations: Zydus Lifesciences Limited

Press Releases: Zydus Lifesciences Limited

News in other languages: Zydus Lifesciences Limited

Quotes and Performance

Course Extremes

Managers and Directors: Zydus Lifesciences Limited

ETFs: Zydus Lifesciences Limited

Generic Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

Zydus receives final approval from USFDA for Scopolamine Transdermal System 1 mg/3 days	02/09	AQ
Zynext Ventures Invests in neuro42, A Company Developing Portable MRI Systems for Neuroimaging and Interventions	15/08	AQ
Zynext Ventures, the VC arm of Zydus Lifesciences, Announces Investment in Promaxo: Pioneering Point-of-Care Medical Imaging and Interventions with Next Generation MRI Systems	18/06	AQ
Sentynl Therapeutics Announces Global Acquisition of Zokinvy for Treatment of Hutchinson-Gilford Progeria Syndrome from Eiger BioPharmaceuticals	06/05	AQ
Zydus launches Mirabegron Extended-Release Tablets in the US	22/04	BU

EXCLUSIVA-Eli Lilly podría lanzar un fármaco contra la obesidad en India el próximo año: presidente ejecutivo	28/02
Biocon : Farmacéuticas indias se vuelven locales para terminar con dependencia de China	23/21/23
Des laboratoires indiens intéressés par les génériques de Sanofi	11/18/11

1 day	+1.65%
1 week	+2.06%
Current month	+2.52%
1 month	+2.33%
3 months	-10.99%
6 months	-8.72%
Current year	+43.69%

Director	Title	Age	Since
Sharvil Pankajbhai Patel CEO	Chief Executive Officer	45	27/11/2009
Nitin Dalsukhrai Parekh DFI	Director of Finance/CFO	-	-
Dhaval Narendra Soni CMP	Compliance Officer	-	07/02/2019

Manager	Title	Age	Since
Sharvil Pankajbhai Patel BRD	Director/Board Member	45	01/04/2007
Mukesh Mangalbhai Patel BRD	Director/Board Member	69	01/08/1997
Pankaj Ramanbhai Patel CHM	Chairman	71	05/10/2011

Name	Weight	AuM	1st Jan change	Investor Rating
WISDOMTREE INDIA EX-STATE-OWNED ENTERPRISES FUND ETF - USD	0.22%	6 M€	+6.07%	-
LEADERSHARES EQUITY SKEW ETF - USD	0.01%	92 M€	+15.66%	-

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
ZYDUS LIFESCIENCES LIMITED	+1.64%	+2.06%	+56.30%	+113.08%	1.16TCr
SUN PHARMACEUTICAL INDUSTRIES LTD.	+0.50%	+1.04%	+46.52%	+138.51%	5.12TCr
OTSUKA HOLDINGS CO., LTD.	-0.66%	-2.26%	+53.47%	+112.76%	3.12TCr
SANDOZ GROUP AG	+0.79%	-2.72%	+40.01%	-	1.88TCr
CIPLA LIMITED	+0.16%	-2.82%	+21.31%	+63.64%	1.38TCr
THE MEDICINES COMPANY	-.--%	+0.14%	-	-	678.76Cr
STADA ARZNEIMITTEL	-.--%	-1.95%	-	-	572.55Cr
ONO PHARMACEUTICAL CO., LTD.	+0.15%	-1.26%	-33.88%	-38.13%	531.44Cr
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-0.03%	-0.23%	+4.45%	+20.22%	523.68Cr
GLENMARK PHARMACEUTICALS LIMITED	-0.43%	-0.85%	+87.46%	+188.84%	512.97Cr
Average	+0.12%	-1.60%	+34.45%	+85.56%	1.55TCr
Weighted average by Cap.	+0.14%	-1.59%	+42.44%	+110.69%

	2025 *	2026 *
Net sales	23TCr 267.77Cr 254.86Cr 236.19Cr 210.07Cr 379.22Cr 420.26Cr 2.94TCr 1.09TCr 9.33TCr 1.01TCr 983.6Cr 41TCr	24TCr 286.35Cr 272.55Cr 252.57Cr 224.65Cr 405.53Cr 449.42Cr 3.15TCr 1.16TCr 9.98TCr 1.08TCr 1.05TCr 44TCr
Net income	4.45TCr 52Cr 50Cr 46Cr 41Cr 74Cr 82Cr 576.03Cr 212.64Cr 1.83TCr 196.9Cr 192.65Cr 7.98TCr	4.63TCr 55Cr 52Cr 48Cr 43Cr 77Cr 86Cr 598.62Cr 220.98Cr 1.9TCr 204.62Cr 200.21Cr 8.29TCr
Net Debt	-2.48TCr -29Cr -28Cr -26Cr -23Cr -41Cr -46Cr -321.23Cr -118.58Cr -1.02TCr -109.8Cr -107.43Cr -4.45TCr	-6.16TCr -73Cr -69Cr -64Cr -57Cr -102.79Cr -113.91Cr -797.15Cr -294.27Cr -2.53TCr -272.48Cr -266.6Cr -11TCr